The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2025 | Advice for community physicians when managing young adults with ALL
Wendy Stock, MD, University of Chicago Medical Centre, Chicago, IL, gives advice for community oncologists when treating young adult patients with acute lymphoblastic leukemia (ALL). Dr Stock advises physicians to become familiar with pediatric regimens and the modifications that may be needed for young adults, as well as to reach out to experienced clinicians for guidance. This interview took place at the 19th International Symposium on Acute Leukemias (ISAL XIX) in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, I think that the key is to try to get experience with these pediatric regimens and to try to adhere to the trials, to the published regimens as closely as possible. With the caveat that young adult patients, as we’ve learned, require special potential modifications that need to be made to dosing and particularly to dosing of asparaginase. And the community physicians should feel free to reach out to people with experience in the field if they’re running into questions or problems in the management of these patients because this is a challenging disease to treat and community physicians often don’t see a lot of ALL...
Yeah, I think that the key is to try to get experience with these pediatric regimens and to try to adhere to the trials, to the published regimens as closely as possible. With the caveat that young adult patients, as we’ve learned, require special potential modifications that need to be made to dosing and particularly to dosing of asparaginase. And the community physicians should feel free to reach out to people with experience in the field if they’re running into questions or problems in the management of these patients because this is a challenging disease to treat and community physicians often don’t see a lot of ALL. It’s a rare disease and therefore to optimize outcomes for the patients it’s appropriate to and perfectly acceptable and desired for them to reach out to people around the world who have experience in these regimens, because it does take, it’s a learning curve. And so it’s important not to feel hesitant about reaching out, I would say.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
